Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

By M. Kris, R. Natale, R. Herbst, T. Lynch, D. Prager, C. Belani, J. Schiller, K. Kelly, H. Spiridonidis, A. Sandler and 6 more. Journal of the American Medical Association (JAMA), 2003

2,649 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/c2e6dfa7197b35869a1c6132c24c57b6101ab328

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. William Pao
2. J. Engelman
3. Adi F. Gazdar
4. P. Jänne
5. Vincent A. Miller
6. M. Kris
7. Birgit Schoeberl
8. H. Shigematsu

In Pulmonary and Respiratory Medicine

1. William Pao
2. B. Hughes
3. B. Chan
4. Adi F. Gazdar
5. J. Engelman
6. Vincent A. Miller
7. P. Jänne
8. M. Kris

Citations in the corpus

• Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer (2004, background): “It is noteworthy that these characteristics and Japanese ethnicity are all predictors of gefitinib sensitivity at least by univariate analysis (4, 5).”
• Predicting ligand-dependent tumors from multi-dimensional signaling features (2017, background): “Therefore, the approvals of EGFR inhibitors in non-small cell lung cancer (NSCLC) and CRC confirm the predicted dependence on EGFR signaling.(53,54) In contrast, the low dependence of NSCLC on HGF signaling might explain the failure of Onartuzumab (MetMAb), a Met blocking antibody in a Phase 3 study”